1. Introduction {#sec1}
===============

Venezuelan equine encephalitis virus (VEEV) is an encephalitogenic *Alphavirus* that belongs to the family *Togaviridae.* VEEV causes febrile illness in humans, characterized by fever, malaise, and vomiting. Infection can progress to the central nervous system (CNS), causing neurological symptoms, including confusion, ataxia, and seizures. VEEV infection initiates a biphasic disease: a peripheral phase, where viral replication occurs in the lymphoid and myeloid tissues, and a neurotrophic phase, where viral replication progresses to the CNS resulting in neuropathology and in some cases fatal encephalitis. Encephalitis develops in approximately 4% of cases with an overall mortality of 1--2% ([@bib31]).

VEEV is endemic in parts of South, Central and North America causing periodic outbreaks of disease. Over 200,000 humans were infected with an epizootic strain (subtype IAB) of VEEV during the 1960\'s outbreak in Columbia ([@bib40]). VEEV is classified as a biosafety level-3 (BSL-3) select agent by both the Centers for Disease Control and Prevention and the United States Department of Agriculture and as a Category B priority pathogen by the National Institute of Allergy and Infectious Diseases due to its ease of aerosolization, low infectious dose, and potential to cause a major public health threat in the United States ([@bib8]). In addition, VEEV was previously weaponized by the former Soviet Union and the United States. Various laboratory accidents have been recorded and reports from animal studies indicate that aerosolized VEEV is highly infectious and could possibly result in higher mortality than that noted with natural infection ([@bib13]; [@bib17]). Currently, there are no FDA approved therapeutics available for the treatment and prevention of VEEV in humans; military personnel and at risk lab workers are vaccinated with the TC-83 strain ([@bib26]), which is an attenuated strain from the virulent VEEV Trinidad donkey (TrD) strain after 83 serial passages in guinea pig heart cells ([@bib23]). Since the TC-83 strain of VEEV is attenuated it can be utilized at BSL-2 as a model to better understand VEEV replication and to assist in therapeutic discovery.

*In vivo* studies of murine brain suggest that astrocytes are an important target for establishing VEEV infection in the CNS ([@bib29]). Astrocytes are the major glial cells of the CNS, outnumbering neurons by over five-fold. These cells play an important role in many normal CNS functions, including, supporting and protecting neurons, maintaining homeostatic balance by regulating neurotransmitter and ion concentrations, and providing structural support. Several neurotrophic viruses are capable of infecting astrocytes leading to severe neurological complications and CNS damage ([@bib5]). It is now well established that VEEV infection causes inflammation of CNS. Infection of primary astrocytes with VEEV subtype IAB V3000 (molecular clone of VEEV TrD ([@bib16])) or attenuated V3010 (cloned avirulent mutant, E2 76Glu to Lys ([@bib1])) released pro-inflammatory cytokines, TNF-α, and iNOS. The attenuated TC-83 strain of VEEV induces pro-inflammatory cytokines such as IFN-Ɣ, IL-1β, IL-6, IL-8, IL-12, and TNF-α, which contribute to the inflammatory microenvironment ([@bib29]; [@bib33]).

We previously demonstrated that infection of U87MG astrocytoma cells with the VEEV TrD strain, epidemic subtype IAB, induces early growth response 1 (EGR1) mRNA and protein expression leading to cell death via the unfolded protein response (UPR) ([@bib4]). The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) arm of the UPR was found to be activated following VEEV infection. EGR1 belongs to the family of immediate early genes, and is a Cys2-His2-type zinc-finger transcription factor associated with growth, cell survival, and apoptosis. Various extracellular stimuli are capable of activating EGR1 mediating cellular stress responses and being a transcription factor, EGR1 promotes the expression of other genes, as well as its own transcription ([@bib27]). Furthermore, EGR1 is a major mediator and regulator of synaptic plasticity and neuronal activity in both physiological and pathological conditions ([@bib10]).

EGR1 is upregulated in astrocytes during other viral infections, including murine coronavirus infection of U87MG astrocytoma cells ([@bib33]), HIV Tat expression in U87MG cells, and HIV-infection of mouse primary astrocytes ([@bib43]). These studies suggest that EGR1 upregulation may be a conserved stress response induced in astrocytes following viral infection. Our prior results demonstrated that the loss of EGR1 resulted in lower susceptibility to VEEV-induced cell death, indicating that EGR1 modulates pro-apoptotic pathways following infection ([@bib4]). However, U87MG cells are a glioma cell line, a characteristic which could potentially lead to significant differences from primary astrocytes in responding to viral infection and replication. Therefore, in the current study, human primary astrocytes were used to determine if EGR1 is activated in primary cells upon VEEV TC-83 infection and to confirm what signaling pathway(s) actively contribute to EGR1 upregulation and apoptosis in VEEV-infected cells.

2. Material and methods {#sec2}
=======================

2.1. Cell culture {#sec2.1}
-----------------

Primary human astrocytes were obtained from Lonza and maintained in Astrocyte growth medium (AGM) BulletKit (CC-3187 & CC-4123). Vero (ATCC CCL-81) cells were maintained in Dulbecco\'s modified minimum essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillin/streptomycin. All cells were maintained at 37 °C with 5% CO~2~.

2.2. Viruses and infections {#sec2.2}
---------------------------

VEEV TC-83 was obtained from BEI Resources. For viral infections, cells were plated in a 6-well (4 × 10^5^ cells/well) or a 12-well (2 × 10^5^ cells/well) plate and incubated overnight. Next day, cells were infected at the specified multiplicity of infection (MOI). Cells were infected for 1 h at 37 °C and rocked every 15 min to ensure adequate coverage. The cells were then washed with phosphate-buffered saline (PBS), and complete growth medium was added back to the cells. Viral supernatants and cells were collected at various times post-infection for further analysis. To determine viral titers, astrocytes were seeded in a 96-well plate at 15,000 cells per well and allowed to incubate overnight at 37 °C and 5% CO~2~. Treatments and infections were performed as described above. Supernatants were collected at the indicated time points and stored at −80 °C until use. Viral titers were determined by crystal violet plaque assay using Vero cells as previously described ([@bib2]).

2.3. RNA isolation and quantitative RT-PCR {#sec2.3}
------------------------------------------

Total RNA extracted from mock-infected or VEEV TC-83-infected astrocytes \[3, 6, 9, and 18 h post infection (hpi)\] was isolated using the RNeasy mini kit (Qiagen) according to the manufacturer\'s instructions. Real-time quantitative PCR (RT-qPCR) was performed using the StepOnePlus™ Real-Time PCR System (Life Technologies). TaqMan Gene Expression Assays were used for EGR1 (Hs00152928_m1) or 18S (Hs99999901_s1). Fold changes were calculated relative to 18S ribosomal RNA and normalized to mock samples using the ΔΔCt method. Detection of viral RNA in astrocytes was determined by RT-qPCR with Invitrogen\'s RNA UltraSense™ One-Step Quantitative RT-PCR System using Integrated DNA Technologies primer pairs (forward, GTGTGACCAAATGACTG, and reverse, ACCGTTGACGACTATAC) and TaqMan probe (5′-6-carboxyfluorescein TCGTCCGCACTGACATCTGTTGC-carboxytetramethylrhodamine-3′) against the viral RNA packaging signal (nt 1057 to 1154) as described previously ([@bib22]). The absolute quantification was done using StepOne software v2.3 based on the threshold cycle relative to the standard curve. The standard curve was determined using serial dilutions of VEEV TC-83 RNA at known concentrations.

2.4. Western blot analyses {#sec2.4}
--------------------------

Protein lysates were collected using Blue Lysis Buffer and analyzed by western blot as previously described ([@bib3]). The recipe for Blue Lysis Buffer consists of: 25 ml 2x Novex Tris-Glycine Sample Loading Buffer SDS (Invitrogen, Cat\# LC2676), 20 ml T-PER Tissue Protein Extraction Reagent (ThermoFisher, Cat\# 78510), 200 μl 0.5M EDTA pH 8.0, 2--3 complete Protease Cocktail tablets for 50 ml, 80 μl 0.1M Na~3~VO~4~, 400 μl 0.1M NaF, 1.3 ml 1M dithiothreitol. Briefly, primary antibodies against capsid of Venezuelan equine encephalitis virus, TC-83 (Subtype IA/B) Capsid (antiserum, Goat) (BEI resources, NR-9403), EGR1 (44D5) (Cell Signaling, Cat\# 4154S), ERK1/2 (Cell Signaling, Cat\# 4695S), PERK (C33E10) (Cell Signaling, Cat\# 3192S), or horse radish peroxidase (HRP)-conjugated β-actin antibody (Abcam, Cat\# ab49900) were diluted in 3% milk solution per the manufacturer\'s recommended dilutions followed by the addition of the appropriate secondary antibody either anti-rabbit HRP-conjugated (Cell Signaling, Cat\# 7074), or anti-goat HRP-conjugated antibody. PDVF membranes were imaged on a Chemidoc XRS molecular imager (Bio-Rad) using the SuperSignal West Femto Maximum Sensitivity Substrate kit (ThermoFisher, Cat\# 34095).

2.5. Inhibitor treatments {#sec2.5}
-------------------------

Cells were treated prior to viral infection (pre-treated) and following the 1 h viral infection (post-treated) with either dimethyl sulfoxide (DMSO), MEK/ERK inhibitor (PD0325901, MedChem Express, Cat\# HY-10254), p38MAPK inhibitor (SB203580, Selleckchem, Cat\# S1076), PI3K inhibitor (PI-103), or PERK inhibitor (GSK2606414, EMD Millipore, Cat\# 516535). The DMSO concentration was equal to the volume of the inhibitors added to the medium and always less than 0.1% of the final sample volume.

2.6. siRNA transfections {#sec2.6}
------------------------

Astrocytes seeded at 2.5 × 10^5^ cells per well in a 12-well plate were transfected with 50 nM siGenome SMARTpool EGR1 (Dharmacon, Cat\# M-006526-01), 100 nM SignalSilence® p44/42 MAPK (Erk1/2) siRNA (Cell Signaling, Cat\# 6560S), 100 nM SignalSilence® PERK siRNA I (Cell Signaling, Cat\# 9024S), or AllStar negative-control small interfering RNA (Qiagen, Cat\# 1027280), using 1.2 μl of the DharmaFECT 1 transfection reagent (Dharmacon, Cat\# T-2001-02). At 48 h post-transfection, cells were infected with VEEV TC-83 (MOI 5) for 1 h. After infection the medium was replaced with fresh medium. At 18hpi or 36hpi lysates were collected for analysis.

2.7. Cell viability assays {#sec2.7}
--------------------------

For cell viability assays, astrocytes were cultured as described above in 96-well white walled plate (Corning, Cat\# 3903) and transfected with siRNAs followed by mock infection or VEEV TC-83 infection at an MOI of 5 for 36hpi. ATP production was measured as an indication of cell viability using the Promega\'s CellTiter-Glo assay (Cat\# G7570).

2.8. Caspase--Glo 3/7 assays {#sec2.8}
----------------------------

For Caspase-Glo 3/7 assays, astrocytes were cultured as described above in a 96-well white walled plate and transfected with siRNAs for 48 h followed by mock infection or VEEV TC-83 infection at MOI of 5 for 18 or 36hpi. Caspase activity was measured using Promega\'s Caspase-Glo 3/7 assay (Cat\# G8090), following the manufacturer\'s instructions.

2.9. Statistics {#sec2.9}
---------------

Unless otherwise noted, all statistical analysis was calculated using an unpaired, two-tailed Student\'s t-test using Graphpad\'s QuickCalcs software. All graphs contain the mean and standard deviations with an n = 3 unless otherwise mentioned.

3. Results {#sec3}
==========

3.1. Replication of VEEV in human primary astrocytes {#sec3.1}
----------------------------------------------------

Experiments were performed to confirm the ability of VEEV to replicate in monolayer cultures of primary human astrocytes. Cells were infected with VEEV at an MOI of 0.1, 1, and 5. Viral replication and cytopathic effects (CPE) were determined at 3, 6, 9, 18, 24, and 48 h post infection (hpi). VEEV replicated effectively in human primary astrocytes reaching maximum titers at all MOIs by 18hpi ([Fig. 1](#fig1){ref-type="fig"} A). CPE were most prevalent at 24hpi with about 75% of cells remaining viable at the highest MOI ([Fig. 1](#fig1){ref-type="fig"}B). By 48hpi only 20% of the cells or less were viable at all MOIs. These results are in agreement with previous studies demonstrating the ability of VEEV to productively infect primary astrocytes ([@bib29]; [@bib32]).Fig. 1**VEEV replicates efficiently in primary astrocytes**. A) Cells were infected with the attenuated strain of VEEV (VEEVTC-83) at multiple MOIs (0.1, 1, and 5). Viral replication was analyzed at 3, 6, 9, 18, 24, and 48hpi via plaque assays. B) Cell viability was determined at 9, 24 and 48hpi using Cell Titer Glo. Mock-infected cells for each timepoint were included as controls and percent viability for mock-infected cells was set to 100%. Data are expressed as the Mean ± SD (n = 3).Fig. 1

3.2. EGR1 expression is induced following VEEV infection of primary astrocytes {#sec3.2}
------------------------------------------------------------------------------

Previously, we demonstrated EGR1 induction following VEEV infection of U87MG astrocytoma cells ([@bib4]). Experiments were performed to determine if EGR1 is also upregulated in VEEV infected primary human astrocytes. Analyses of RT-qPCR data demonstrated that EGR1 was upregulated in VEEV-infected astrocytes compared to mock-infected cells. EGR1 mRNA upregulation was observed starting at 9hpi with a more dramatic upregulation at 18hpi ([Fig. 2](#fig2){ref-type="fig"} A). EGR1 gene upregulation also correlated with higher levels of viral RNA production ([Fig. 2](#fig2){ref-type="fig"}B). Similarly, EGR1 protein expression was significantly elevated in cells infected at MOI of 5 (mean= 1.526 fold change, p-value equals 0.0002) compared to mock-infected (mean=1 fold change) or those infected at MOI of 1 (mean=1.17 fold change) at 18hpi ([Fig. 2](#fig2){ref-type="fig"}C and D). These data confirm that EGR1 upregulation is a conserved response to VEEV infection in primary astrocytes.Fig. 2**EGR1 expression is induced following VEEV infection in primary astrocytes**. A) Primary astrocytes were infected with VEEV TC-83 at an MOI of 1 and total RNA extracted at 3, 6, 9, and 18hpi. Gene expression was determined using TaqMan assays for EGR1. Fold changes were calculated relative to 18S ribosomal RNA and normalized to mock samples using the ΔΔCt method. B) Cells were infected and RNA extracted as above in panel A. Viral genomic copies were determined by RT-qPCR. Results are displayed as genomic copies in logarithmic scale. C) Astrocytes were mock-infected or infected with TC-83 (MOI 1 or 5) for 1 h. At 18hpi, cell lysates were collected using blue lysis buffer and analyzed by immunoblot. PVDF membranes were probed to determine levels of EGR1 and VEEV capsid. β-Actin was used as a loading control. D) EGR1 protein levels were normalized to β-Actin. Data are expressed as the Mean ± SD (n = 3). \*p-value≤ 0.05, \*\*p-value ≤0.01, \*\*\*p-value ≤ 0.001.Fig. 2

3.3. EGR1 expression is dependent on ERK and PERK signaling {#sec3.3}
-----------------------------------------------------------

VEEV infection of U87MG cells induces the PERK arm of the UPR activating EGR1 mRNA and protein expression leading to VEEV-induced cell death or apoptosis ([@bib4]). However, EGR1 expression can also be stimulated by extracellular signal-regulated kinase (ERK), p38 mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways ([@bib27]) and there is significant crosstalk between MAPK signaling and the UPR ([@bib9]). To determine if ERK, p38, PI3K, or PERK are necessary for EGR1 induction, we tested well characterized small molecule kinase inhibitors. EGR1 transcripts were significantly downregulated in both mock and VEEV-infected cells treated with an ERK inhibitor (ERKi, PD0325901). Over a 6-fold decrease in EGR1 gene expression (mean= 0.058 fold change) was observed in ERKi treated and VEEV-infected cells compared to DMSO treated and VEEV-infected (mean=6.35 fold change, p-value equals 0.0001) ([Fig. 3](#fig3){ref-type="fig"} A). Similarly, treatment with a PERK inhibitor (PERKi, GSK2606414) also suppressed EGR1 expression in VEEV-infected cells by over four-fold (mean= 3.02 fold change) compared to DMSO treated and VEEV-infected cells (mean=7.62 fold change, p-value equals 0.0003) ([Fig. 3](#fig3){ref-type="fig"}C). Treatment with a p38MAPK inhibitor (p38MAPKi, SB203580) had no significant impact on EGR1 expression (n.s.) ([Fig. 3](#fig3){ref-type="fig"}A). Treatment with PI3K inhibitor (PI3Ki, PI-103) elevated EGR1 expression (mean= 17.8 fold change) compared to DMSO treated and VEEV-infected cells (mean=11.3 fold change, p-value equals 0.049) ([Fig. 3](#fig3){ref-type="fig"}B). Overall, these results demonstrate that EGR1 expression is induced following VEEV infection through ERK- and PERK-dependent pathways. Since ERK and PERK inhibitors had a major impact in suppressing EGR1 expression, subsequent studies focused on ERK and PERK pathways.Fig. 3**EGR1 expression is dependent on ERK and PERK signaling**. A-C) Primary astrocytes were mock-infected or infected with TC-83 (MOI 5) for 1 h and pre- and post-treated with either DMSO, ERKi (10 μM), p38MAPKi (10 μM), PI3Ki (500 nM), or PERKi (2.5  μM). At 18hpi total RNA was extracted and gene expression was determined using TaqMan assays for EGR1. Fold changes were calculated relative to 18S ribosomal RNA and normalized to mock samples using the ΔΔCt method. Data are expressed as the Mean ± SD (n = 3). \*p-value ≤ 0.05, \*\*\*p-value ≤ 0.001, \*\*\*\*p-value≤ 0.0001. n.s. =not significantFig. 3

3.4. Loss of EGR1 reduces VEEV-induced apoptosis and impacts viral replication in primary astrocytes {#sec3.4}
----------------------------------------------------------------------------------------------------

Since EGR1 is at least partially responsible for VEEV-induced cell death in U87MG astrocytes, the impact of EGR1 on apoptosis in primary astrocytes was assessed. Primary astrocytes were transfected with siRNA targeting EGR1 prior to VEEV infection. At 18hpi, lysates were collected for western blot analysis. EGR1 protein expression was significantly reduced in cells treated with siRNA against EGR1 indicating successful knockdown ([Fig. 4](#fig4){ref-type="fig"} A and B). As expected, negative control siRNA (siNeg) transfected and VEEV-infected cells had increased expression of EGR1 compared to siNeg treated and mock-infected cells. A modest, but significant, decrease in viral RNA was observed in siEGR1 transfected and VEEV infected cells by nearly 1 log (mean= 1.7e8 genomic copies) compared to siNeg transfected and VEEV infected cells (mean= 2.6e9 genomic copies, p-value equals 0.04) indicating that loss of EGR1 impacts viral replication ([Fig. 4](#fig4){ref-type="fig"}C). Increased caspase 3/7 activity was observed following VEEV infection and loss of EGR1 in VEEV infected cells significantly reduced caspase 3/7 activity by more than 2-fold compared to cells transfected with siNeg ([Fig. 4](#fig4){ref-type="fig"}D). These data indicate that loss of EGR1 limits viral induced apoptosis in primary astrocytes in addition to impacting viral replication.Fig. 4**Loss of EGR1 blocks VEEV-induced apoptosis in primary astrocytes**. Primary astrocytes were transfected with a negative-control (siNeg) or siRNA targeting EGR1 (siEGR1) at 50 nM. At 48 h post-transfection, cells were infected with VEEVTC-83 (MOI 5) or mock-infected. At 18hpi, A) Cell lysates were collected using blue lysis buffer and analyzed by western blot. PVDF membranes were probed for levels of EGR1 and β-Actin was used as a loading control. B) EGR1 protein levels were normalized to β-Actin. Data are expressed as the Mean ± SD (n = 3). C) Total RNA was extracted and viral genomic copies were determined by RT-qPCR. Results are displayed as genomic copies in logarithmic scale. Data are expressed as the Mean ± SD (n = 4) D) Caspase-3/7 activity was measured using the Caspase-Glo 3/7 assay (Promega). Data are expressed as the Mean ± SD (n = 4). \*p-value ≤ 0.05, \*\*p-value ≤ 0.01.Fig. 4

3.5. ERK1/2 siRNA reduces EGR1 expression and significantly impacts viral replication {#sec3.5}
-------------------------------------------------------------------------------------

To confirm that EGR1 expression was dependent on the ERK pathway and to determine its impact on viral replication, siRNA knockdown against ERK1/2 was performed. At 48 h post transfection, lysates were collected for western blot analysis. ERK1/2 protein expression was significantly reduced in cells treated with each concentration of ERK1/2 siRNA tested, indicating a successful knockdown of ERK1/2 ([Fig. 5](#fig5){ref-type="fig"} A). To ensure a robust knockdown, 100 nM of siRNA was selected for subsequent studies. siRNA transfection was followed by mock or VEEV infection and at 18hpi total RNA was extracted to determine EGR1 expression. siERK1/2 transfected and VEEV infected cells had a significant and dramatic decrease in EGR1 mRNA expression by nearly 10-fold (mean=0.65 fold change) compared to siNeg and TC-83 infected cells (mean=10.4 fold change) (p-value equals 0.006) ([Fig. 5](#fig5){ref-type="fig"}B) indicating that EGR1 expression is dependent on the ERK pathway. Similarly, a significant and dramatic decrease (about 5 log) in viral RNA was observed in siERK1/2 transfected cells (mean= 2.2e5 genomic copies) compared to siNeg transfected cells (mean= 1.02e10 genomic copies, p-value equals 0.0001) ([Fig. 5](#fig5){ref-type="fig"}C). These data confirm that ERK is important for induction of EGR1 gene expression and that downregulating ERK1/2 reduces VEEV viral RNA production.Fig. 5**Knockdown of ERK1/2 decreases EGR1 expression and viral RNA**. A) Primary astrocytes were transfected with various concentrations of either negative-control (siNeg) or siRNA targeting ERK1/2 (siERK1/2). At 48 h post transfection, cell lysates were collected in blue lysis buffer and analyzed by western blot. PVDF membranes were probed for levels of ERK1/2 and β-Actin was used as a loading control. B) Cells were transfected with 100 nM siNeg or siERK1/2 siRNAs for 48 h and then infected with VEEV TC-83 (MOI 5) or mock-infected. At 18hpi, total RNA was extracted and gene expression was determined using TaqMan assays for EGR1. Fold changes were calculated relative to 18S ribosomal RNA and normalized to mock samples using the ΔΔCt method. C) RNA collected as described in panel B was used for viral genomic copy determination by RT-qPCR. Results are displayed as genomic copies in logarithmic scale. Data are expressed as the Mean ± SD (n = 3). \*\*p-value ≤0.01, \*\*\*p-value ≤ 0.001.Fig. 5

3.6. PERK siRNA reduces EGR1 expression and significantly impacts viral replication {#sec3.6}
-----------------------------------------------------------------------------------

We further tested if knockdown of PERK would have a similar impact on EGR1 as well as viral replication. Cells were transfected with siNeg or PERK siRNA at increasing concentrations. Lysates were collected at 48 h post transfection and PERK expression was analyzed by western blot analysis. PERK protein expression was significantly reduced in cells transfected with each concentration of siPERK tested, indicating successful knockdown of PERK ([Fig. 6](#fig6){ref-type="fig"} A). To ensure a robust knockdown, 100 nM of siRNA was selected for subsequent studies. We next assessed the levels of EGR1 mRNA expression in cells transfected with siPERK and infected with VEEV. Similar to the siERK1/2 data, knockdown of PERK significantly reduced EGR1 expression by nearly 10-fold in VEEV-infected cells (mean=0.74 fold change) compared to siNeg transfected and VEEV infected cells (mean=10.26 fold change, p-value equals 0.0001). Likewise, viral RNA decreased by nearly 5 log fold in siPERK transfected and VEEV infected cells (mean=8.7e4 genomic copies) compared to siNeg-transfected and VEEV-infected cells (mean=6.8e9 genomic copies) (p-value equals 0.0001). These data indicate that EGR1 expression is also regulated by PERK and loss of PERK decreases VEEV viral RNA production.Fig. 6**Knockdown of PERK decreases EGR1 expression and viral RNA**. A) Primary astrocytes were transfected with various concentrations of a negative-control (siNeg) or siRNA targeting PERK (siPERK). At 48 h post transfection, cell lysates were collected using blue lysis buffer and analyzed by western blot. PVDF membranes were probed for levels of ERK1/2 and β-Actin as a loading control. B) Cells were transfected with 100 nM siNeg or siPERK siRNAs for 48 h and then infected with VEEV-TC83 (MOI 5) or mock-infected. At 18hpi, total RNA was extracted and gene expression was determined using TaqMan assays for EGR1 gene. Fold changes were calculated relative to 18S ribosomal RNA and normalized to mock samples using the ΔΔCt method. C) RNA collected as described in panel B was used for viral genomic copy determination by RT-qPCR. Results are displayed as genomic copies in logarithmic scale. Data are expressed as the Mean ± SD (n = 3). \*\*p-value ≤0.01, \*\*\*\*p-value ≤ 0.0001.Fig. 6

3.7. Loss of ERK1/2 or PERK increases cell viability and blocks VEEV induced apoptosis in VEEV infected astrocytes {#sec3.7}
------------------------------------------------------------------------------------------------------------------

Since blocking either the ERK or the PERK pathway had a major impact on EGR1 expression as well as VEEV replication in primary astrocytes, we next assessed the impact of loss of ERK1/2 and PERK on cell survival following VEEV infection. Cells were transfected with siRNAs targeting ERK1/2, PERK, or siNeg followed by VEEV infection. At 36hpi, cell viability was measured using the CellTiter Glo assay and caspase 3/7 activity was measured using the Caspase-Glo 3/7 assay. Less than 50% of cells were viable in siNeg-transfected and VEEV-infected cells ([Fig. 7](#fig7){ref-type="fig"} A and C). Cells transfected with siERK1/2 and VEEV-infected had cell viability over 78% (p value equals 0.003) ([Fig. 7](#fig7){ref-type="fig"}A). Similarly, cells transfected with siPERK and VEEV-infected had a significant improvement in cell viability ([Fig. 7](#fig7){ref-type="fig"}C). Caspase-3/7 activity was highly impacted in cells transfected with siERK1/2 or siPERK and VEEV-infected. A dramatic reduction in VEEV induced apoptosis was observed in siERK1/2 transfected cells by nearly 3-fold compared to siNeg-transfected cells (p-value equals 0.0001) ([Fig. 7](#fig7){ref-type="fig"}B). Similarly, nearly 4-fold reduction in VEEV induced apoptosis was observed in siPERK transfected and VEEV-infected cells compared to siNeg transfected and VEEV-infected cells (p-value equals 0.0001). No visible CPE was evident in siERK1/2 or siPERK transfected and VEEV infected cells even after 36hpi when observed under microscope (data not shown). These data indicate that loss of PERK and ERK impedes VEEV induced cell death.Fig. 7**Knockdown of ERK1/2 or PERK increases cell viability as well as rescues cells from VEEV induced apoptosis**. Primary astrocytes were transfected with siNeg, siERK1/2, or siPERK siRNAs at 100 nM. At 48 h post transfection, cells were infected with VEEV-TC83 (MOI 5) or mock-infected and at 36hpi, A and C) Percent cell viability was measured using CellTiter-Glo assay. B and D) Caspase-3/7 activity was measured using Caspase-Glo 3/7 assay. Data was normalized to siNeg-transfected and mock-infected cells. Data are expressed as the Mean ± SD (n = 3). \*\*p-value ≤0.01, \*\*\*p-value ≤ 0.001, \*\*\*\*p-value ≤ 0.0001.Fig. 7

4. Discussion {#sec4}
=============

Astrocytes and neurons are the primary targets of VEEV in the brain ([@bib6]) inducing well-characterized cytopathic effects in neurons of the CNS. In this study, we showed that VEEV replication in human primary astrocytes and the apoptosis induced following VEEV infection can be suppressed by blocking either ERK or PERK pathways, both of which are responsible for upregulating EGR1 pathway, rescuing the cells from VEEV induced apoptosis. Cytopathic effects in primary astrocytes following VEEV infection has been shown in previous published studies ([@bib29]; [@bib32]). Substantial amounts of astrocyte cell death due to VEEV-astrocyte interaction could contribute to decreased neuronal survival and long-term CNS damage.

We demonstrated that EGR1 expression is increased following VEEV TC83 infection in human primary astrocytes at both the mRNA and protein levels. These studies are in agreement with our previous study which showed that EGR1 upregulation contributed to VEEV TrD-induced apoptosis in U87MG astrocytoma cells ([@bib4]). A caveat of our current work is that all of our data were produced using infection of primary astrocytes with VEEV TC-83. VEEV TC-83 is a live attenuated vaccine strain of VEEV that has investigational new drug status and can only be used for vaccination of animals and individuals, such as military personnel, that are at risk for VEEV exposure ([@bib35]). While VEEV TC-83 replicates efficiently *in vitro* *,* it has limited pathogenicity in mouse models of infection with most strains of mice surviving infection and displaying less severe brain pathology as compared to VEEV TrD infection ([@bib37]; [@bib20]). However, our current data coupled with our previous work indicate that EGR1 upregulation and its subsequent induction of apoptosis are induced by both VEEV TC-83 and TrD infections.

Our data also indicate that EGR1 expression following VEEV infection was dependent on both the ERK and PERK signaling pathways which was determined by inhibitor treatments and confirmed by siRNA transfections. ERK signaling is a central MAPK pathway and ERK proteins are critical members of the Ras-Raf-MEK-ERK signaling pathway, activated by various stimuli, and play an important role in cell proliferation, differentiation, survival, learning, and sometimes apoptosis ([@bib36]). The ERK proteins are abundantly expressed throughout the brain ([@bib42]) and the ERK pathway has been shown to activate EGR1 induced by nerve-growth factor, which in turn mediates p35 induction, leading to neuronal differentiation ([@bib18]). Activated ERK is known to phosphorylate serine/threonine residues of more than 50 downstream cytosolic and nuclear substrates ([@bib34]; [@bib28]). Amoung these substrates, ERK phosphorylates the transcription factor Elk-1 ([@bib7]), which in turn induces EGR1 gene expression ([@bib38]; [@bib11]). Previous work has shown the MAPK transduction pathways as key players in the cell death of rat cortical astrocytes ([@bib12]), which is in agreement with our results. EGR1 activation and upregulation via the ERK signaling cascade has also been observed in melanoma cells ([@bib14]), prostate cancer cells ([@bib15]), and in breast cancer cell lines ([@bib41]), implying that EGR1 induction may be a conserved stress response not only in astrocytes, but also other cell types.

The UPR maintains the homeostasis of cellular proteins by preventing the excessive accumulation of misfolded or unfolded proteins in the lumen of the ER during normal and aberrant conditions ([@bib30]). The PERK pathway of the UPR, is involved in both survival and apoptotic signaling. PERK-mediated phosphorylation of eIF2α prevents ER stress-induced apoptosis whereas, under severe cell ER stress, the PERK-eIF2α-ATF4 pathway activates transcription of pro-apoptotic factors, such as C/EBP homologous protein (CHOP) and growth arrest and DNA damage-inducible protein GADD34 enhancing apoptosis signaling ([@bib21]; [@bib25]). Indeed, in VEEV-infected U87MG cells, CHOP expression was induced ([@bib4]). Our data suggest that PERK activity is stimulated following infection due to the accumulation of large amounts of viral glycoproteins in the ER causing ER stress which can activate UPR signaling cascades ([@bib37]), ultimately leading to EGR1 activation in infected cells ([@bib5]).

Our results showed that even though suppressing EGR1 had an impact on viral replication as well as rescued astrocytes from VEEV induced cell death, blocking the ERK or the PERK pathway had a more dramatic effect on viral replication. Inhibition of ERK signaling through small molecule inhibitors was previously shown to suppress VEEV replication ([@bib39]), supporting the importance of the ERK pathway for VEEV replication. These data indicate that blocking EGR1 alone is not sufficient to dramatically impact VEEV replication, in agreement with our previous data where VEEV TrD replication in wildtype and EGR1 −/− mouse embryonic fibroblasts (MEFs\_) was comparable ([@bib4]). Given that ERK phosphorylates more than 50 substrates ([@bib34]; [@bib28]) and PERK stimulates multiple signaling components including other transcription factors (ATF4, Nrf2, CHOP ([@bib19])) the observed impact on viral replication may be peripheral to their regulation of EGR1 gene expression. Alternatively, since a modest impact on viral replication was observed following loss of EGR1, a combination of multiple ERK or PERK regulated factors may be needed to strongly impact VEEV replication. However, loss of EGR1 was sufficient to reduce VEEV induced apoptosis, indicating that its role is related to regulation of cell death pathways rather than impacting viral replication.

Taken together, our data leads to a proposed model of EGR1 regulated astrocyte cell death following VEEV infection ([Fig. 8](#fig8){ref-type="fig"} ). On one hand, VEEV infection leads to activation of the ERK signaling cascade in cells ([@bib39]), activating EGR1 gene expression. While on the other hand, viral infection leads to ER stress in cells, activating the PERK arm of the UPR pathway which in turn contributes to EGR1 activation. ([@bib4]). Previous studies have shown significant cross talk between ERK signaling and endoplasmic reticulum stress in cancer, atherosclerosis, and ischemia. During ER stress, PERK and ATF6 promote ERK and p38 phosphorylation thus boosting pro-inflammatory cytokine secretion in bronchial epithelial cells ([@bib24]). However, ERK phosphorylation is induced at early time points (5 min to 6 h) following VEEV infection, suggesting that there is an early induction of ERK activity ([@bib39]) and a later ER stress stimulated ERK activity in VEEV infected cells. Activated EGR1 then translocates to the nucleus leading to the activation of various EGR1 regulated genes ultimately contributing to apoptosis. Blocking the ERK or PERK pathways suppresses EGR1 gene expression, which in turn can block viral-induced apoptosis leading to cell survival. The mechanism by which EGR1 contributes to apoptosis is largely unknown. Ongoing studies in our lab are aimed at identifying EGR1 responsive genes to begin to elucidate EGR1-dependent gene expression changes that contribute to VEEV-induced cell death.Fig. 8**Proposed model of EGR1 regulated human primary astrocyte cell death following VEEV infection**. Following VEEV infection of astrocytes, the ERK signaling cascade is activated. The PERK arm of the UPR is also induced due to the accumulation of viral glycoproteins with the ER. Both ERK and PERK pathways contribute to the induction of EGR1 (at the transcription level). EGR1 contributes to VEEV induced cell death through an undetermined mechanism, which is likely due to transcriptional regulation of apoptotic factors.Fig. 8
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